Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from AbCellera Biologics ( (ABCL) ) is now available.
On May 30, 2025, AbCellera Biologics announced it received a No Objection Letter from Health Canada, authorizing its Clinical Trial Application for ABCL575, an investigational antibody antagonist targeting the OX40 ligand for treating moderate-to-severe atopic dermatitis. The Phase 1 clinical trial is expected to commence in Q3 2025, focusing on evaluating the safety and pharmacokinetics of ABCL575 in healthy participants. This development signifies a step forward in AbCellera’s efforts to address inflammatory and autoimmune conditions, potentially enhancing its market position and offering new treatment options for stakeholders.
The most recent analyst rating on (ABCL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.
Spark’s Take on ABCL Stock
According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.
The overall stock score of 47 reflects significant financial and technical challenges, with declining revenues and weak technical indicators being the primary concerns. While strategic advancements and a strong liquidity position offer some optimism, the negative earnings outlook poses substantial risks.
To see Spark’s full report on ABCL stock, click here.
More about AbCellera Biologics
AbCellera Biologics Inc. is a company that discovers and develops antibody medicines for various therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. The company integrates technology, data science, infrastructure, and interdisciplinary teams to address complex antibody discovery challenges, focusing on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development with partners.
Average Trading Volume: 4,073,245
Technical Sentiment Signal: Sell
Current Market Cap: $608.9M
See more insights into ABCL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue